WO2012134135A3 - Spermine copolymer and gene therapy using the spermine copolymer as a nucleic-acid carrier - Google Patents

Spermine copolymer and gene therapy using the spermine copolymer as a nucleic-acid carrier Download PDF

Info

Publication number
WO2012134135A3
WO2012134135A3 PCT/KR2012/002194 KR2012002194W WO2012134135A3 WO 2012134135 A3 WO2012134135 A3 WO 2012134135A3 KR 2012002194 W KR2012002194 W KR 2012002194W WO 2012134135 A3 WO2012134135 A3 WO 2012134135A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic
spermine
acid carrier
spermine copolymer
copolymer
Prior art date
Application number
PCT/KR2012/002194
Other languages
French (fr)
Korean (ko)
Other versions
WO2012134135A2 (en
Inventor
조명행
강호림
Original Assignee
서울대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교산학협력단 filed Critical 서울대학교산학협력단
Publication of WO2012134135A2 publication Critical patent/WO2012134135A2/en
Publication of WO2012134135A3 publication Critical patent/WO2012134135A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
    • C08F20/10—Esters
    • C08F20/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/103—Esters of polyhydric alcohols or polyhydric phenols of trialcohols, e.g. trimethylolpropane tri(meth)acrylate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

The present invention relates to a spermine copolymer and to gene therapy using the spermine copolymer as a nucleic-acid carrier. The spermine copolymer of the present invention is formed by copolymerizing spermine (SPE) using a linker compound that contains two or more hydroxyl groups, and thus may exhibit superior binding capacity in therapeutic nucleic acids such as DNA, effectively protect DNA from nucleases, and exhibit physico-chemical properties appropriate for use as a nucleic-acid carrier. Further, the hydroxyl groups of the linker compound may prevent the access of other blood proteins and the resulting aggregation thereof to achieve the improved stability of the nucleic-acid carrier in the blood, thereby exhibiting extremely low in vitro and in vivo cytotoxicity and extremely high transduction efficiency. Therefore, the spermine copolymer of the present invention may be effectively used as a nucleic acid carrier for gene therapy.
PCT/KR2012/002194 2011-03-25 2012-03-26 Spermine copolymer and gene therapy using the spermine copolymer as a nucleic-acid carrier WO2012134135A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110027191 2011-03-25
KR10-2011-0027191 2011-03-25

Publications (2)

Publication Number Publication Date
WO2012134135A2 WO2012134135A2 (en) 2012-10-04
WO2012134135A3 true WO2012134135A3 (en) 2013-01-10

Family

ID=46932097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002194 WO2012134135A2 (en) 2011-03-25 2012-03-26 Spermine copolymer and gene therapy using the spermine copolymer as a nucleic-acid carrier

Country Status (2)

Country Link
KR (1) KR101459185B1 (en)
WO (1) WO2012134135A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102056144B1 (en) 2018-03-08 2019-12-16 주식회사 파마리서치프로덕트 Fluid composition containing higher concentrations of fragmented DNA mixtures and a method for manufacturing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100645A1 (en) * 2008-01-25 2009-08-20 Tuo Jin Polycationic gene carriers formed of endogenous amino group-bearing monomers
WO2010065660A2 (en) * 2008-12-02 2010-06-10 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
EP1966442B1 (en) * 2005-12-22 2014-03-05 Clariant Finance (BVI) Limited Dry strength system for the production of paper and board
KR100942807B1 (en) * 2007-12-26 2010-02-18 재단법인서울대학교산학협력재단 Gene Therapy and Pharmaceutical Composition for Preventing or Treating Lung Cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100645A1 (en) * 2008-01-25 2009-08-20 Tuo Jin Polycationic gene carriers formed of endogenous amino group-bearing monomers
WO2010065660A2 (en) * 2008-12-02 2010-06-10 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAVALLARO G. ET AL.: "Polyhydroxyethylaspartamide-spermine copolymers: Efficient vectors for gene delivery.", JOURNAL OF CONTROLLED RELEASE, vol. 131, no. 1, 6 October 2008 (2008-10-06), pages 54 - 63, XP025506369, DOI: doi:10.1016/j.jconrel.2008.07.001 *
JIANG, HU LIM ET AL.: "Chitosan-graft-spermine as a gene carrier in vitro and in vivo.", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS., vol. 77, no. 1, 31 January 2011 (2011-01-31), pages 36 - 42, XP027571342 *

Also Published As

Publication number Publication date
WO2012134135A2 (en) 2012-10-04
KR20120111719A (en) 2012-10-10
KR101459185B1 (en) 2014-11-07

Similar Documents

Publication Publication Date Title
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2017053431A3 (en) Allele selective gene editing and uses thereof
EP4279610A3 (en) Ribonucleic acid purification
WO2015089368A3 (en) Complement component irna compositions and methods of use thereof
WO2012078536A3 (en) Double stranded oligonucleotide compounds comprising threose modifications
WO2010041913A3 (en) Novel uses of grs proteins or fragments thereof
BR112015004747A2 (en) p53 double stranded oligonucleotide molecules and methods of using them
WO2013143700A3 (en) Artificial nucleic acid molecules comprising a 5'top utr
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EA201070421A1 (en) MICRORIPONIC ACID
WO2013163430A3 (en) Serpinc1 irna compositions and methods of use thereof
EP3290055A3 (en) Recombinant virus products and methods for inhibition of expression of dux4
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
EP2471926A3 (en) Immunostimulatory oligodeoxynucleotides
WO2013058482A3 (en) Multi-functional nucleic acid-based anti-cancer drug capable of targeting and therapy, method for preparing same and anti-cancer composition comprising same
MX2013007537A (en) Pharmaceutical formulation comprising a biopharmaceutical drug.
WO2010120508A3 (en) Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders
WO2014111876A3 (en) Modulation of mitophagy and use thereof
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2014066915A3 (en) Methods and compositions to produce ss-rnai activity with enhanced potency
WO2013096958A8 (en) Compositions and methods for the delivery of biologically active rnas
WO2012011114A3 (en) Sequence specific double-stranded dna/rna binding compounds and uses thereof
EP1892293A4 (en) Transcription factor decoy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12763348

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12763348

Country of ref document: EP

Kind code of ref document: A2